Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Recruiting now
Conditions studied: Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
In brief
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment have been limited by small sample sizes in single center studies and misclassification in registry studies. Recent advances in the understanding of the mechanisms of FSGS in the native kidney has reinvigorated the scientific community to develop a collaborative community to advance research into the epidemiology, mechanisms, interventions, and outcomes. The purpose of RESOLVE is to gather a group of people with FSGS and MCD that have had or will have a kidney transplant to create a bank of information and biospecimens so researchers can more effectively study these diseases.
Key facts
- Study ID
- NCT05650619
- Run by
- University of Michigan
- People needed
- 300
- Starts
- 2022-12-08
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-04-29
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Retrospective non-consented participant group had a transplant from the year 2000 and onward.
- Diagnosis of FSGS or MCD in the native kidney (prior to transplant).
You may not qualify if…
- Pathologic diagnosis other than FSGS or MCD
- FSGS or MCD secondary to a known disorder (e.g. lupus nephritis, Immunoglobulin A (IgA) nephropathy, malignancy)
Where it is running
- University of Michigan — Ann Arbor, Michigan, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.